IL299308A - Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine - Google Patents

Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Info

Publication number
IL299308A
IL299308A IL299308A IL29930822A IL299308A IL 299308 A IL299308 A IL 299308A IL 299308 A IL299308 A IL 299308A IL 29930822 A IL29930822 A IL 29930822A IL 299308 A IL299308 A IL 299308A
Authority
IL
Israel
Prior art keywords
ylethanamine
pyridin
phenyl
cutaneous
formulations
Prior art date
Application number
IL299308A
Other languages
English (en)
Hebrew (he)
Inventor
Robert Berman
Rajesh Kumar
Charles M Conway
Mary K Donohue
Ajaya Kumar Reka
Original Assignee
Biohaven Therapeutics Ltd
Robert Berman
Rajesh Kumar
Charles M Conway
Mary K Donohue
Ajaya Kumar Reka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd, Robert Berman, Rajesh Kumar, Charles M Conway, Mary K Donohue, Ajaya Kumar Reka filed Critical Biohaven Therapeutics Ltd
Publication of IL299308A publication Critical patent/IL299308A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
IL299308A 2020-06-23 2021-06-23 Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine IL299308A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043075P 2020-06-23 2020-06-23
PCT/US2021/038564 WO2021262779A1 (en) 2020-06-23 2021-06-23 Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Publications (1)

Publication Number Publication Date
IL299308A true IL299308A (en) 2023-02-01

Family

ID=79281832

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299308A IL299308A (en) 2020-06-23 2021-06-23 Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Country Status (12)

Country Link
US (1) US12564579B2 (cg-RX-API-DMAC7.html)
EP (1) EP4168116A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023531918A (cg-RX-API-DMAC7.html)
KR (1) KR20230026449A (cg-RX-API-DMAC7.html)
CN (1) CN115836052A (cg-RX-API-DMAC7.html)
AU (1) AU2021297823A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025900A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187140A1 (cg-RX-API-DMAC7.html)
IL (1) IL299308A (cg-RX-API-DMAC7.html)
MX (1) MX2022016183A (cg-RX-API-DMAC7.html)
PH (1) PH12022553502A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021262779A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240350409A1 (en) * 2023-04-20 2024-10-24 LifeActive, Inc. Transdermal delivery formulations and methods for the manufacture thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU655840B2 (en) * 1991-07-17 1995-01-12 Pfizer Inc. 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents
NZ251384A (en) * 1992-04-03 1996-10-28 Fisons Corp (s)-enantiomer of 1-phenyl-2-(2-pyridinyl) ethylamine and medicaments
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
KR102336426B1 (ko) 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda 길항제 전구약물
US11358935B2 (en) * 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
US12090145B2 (en) * 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases

Also Published As

Publication number Publication date
KR20230026449A (ko) 2023-02-24
AU2021297823A1 (en) 2023-02-16
EP4168116A1 (en) 2023-04-26
JP2023531918A (ja) 2023-07-26
EP4168116A4 (en) 2024-07-10
CA3187140A1 (en) 2021-12-30
WO2021262779A1 (en) 2021-12-30
US20230190719A1 (en) 2023-06-22
BR112022025900A2 (pt) 2023-01-10
MX2022016183A (es) 2023-02-13
PH12022553502A1 (en) 2024-04-22
US12564579B2 (en) 2026-03-03
CN115836052A (zh) 2023-03-21

Similar Documents

Publication Publication Date Title
MA50205A (fr) Formulation de nicotine
EP4444240A4 (en) AXILLARY CRUTCH
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
EP4244818A4 (en) Disambiguation of poses
IL281976A (en) Anti-fgfr2 antibody formulations
IL280047A (en) Formulation of cannabinoid compounds
MX2019011613A (es) Formulaciones de acido 1-amino-1-ciclopropanocarboxilico.
MX2020006016A (es) Polimorfos.
IL305851A (en) Preparation of 2-chloro-4-fluoro-5-nitrobenzoic acid
HUE065395T2 (hu) Mikromûanyagok elválasztása
IL307342A (en) Formulations of apremilast
IL285765A (en) Therapeutic uses of dulaglutide
IL285119A (en) Use of spiropidion
EP4284362A4 (en) Formulations
EP4062913C0 (en) SOLID ORAL FORMULATION OF UTIDELONE
IL281519A (en) Stable intranasal formulations of carbetocin
IL312977A (en) Formulations of pyrrolopyridine-aniline compounds
EP4168116A4 (en) Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine
EP4142696C0 (en) SOLID FORMULATIONS OF CORALLOPYRONINE A
CR20240192A (es) Composiciones farmacéuticas de efruxifermina
IL310652A (en) Formulations of radiprodil
EP4188088A4 (en) Formulations
EP4175676A4 (en) MUCO-PENETRATING FORMULATIONS
EP4395765A4 (en) INTRAVENOUS FORMULATIONS OF RK-33
PL3879173T3 (pl) Zestaw komponentów zasilanych prądem